Skip to main content

June 2018- Despite high prevalence of HIV in SSA, descriptions of Plasmablastic lymphoma (PBL) are scare.  In one of the first clinical descriptions of PBL, we report on characteristics, treatment, and outcomes of 12 pathologically confirmed PBL cases in Lilongwe.

Plasmablastic lymphoma in Malawi


Zuze, Takondwa; Painschab, Matthew S.; Seguin, Ryan; Kudowa, Evarista; Kaimila, Bongani; Kasonkanji, Edwards; Tomoka, Tamiwe; Dhungel, Bal Mukunda; Mulenga, Maurice; Chikasema, Maria; Tewete, Blessings; Ntangwanika, Asekanadziwa; Chiyoyola, Sarah; Chimzimu, Fred; Kampani, Coxcilly; Krysiak, Robert; Montgomery, Nathan D.; Fedoriw, Yuri; Gopal, Satish


Infectious Agents and Cancer


Access the text here.



Plasmablastic lymphoma (PBL) clinical descriptions are scarce from sub-Saharan Africa (SSA) where both HIV and EBV are highly endemic. We identified 12 patients with pathologically confirmed PBL from a prospective cohort in Lilongwe, Malawi. Median age was 46 (range 26–71), seven (58%) were male, and six (50%) were HIV-positive. Eight patients were treated with CHOP and four with a modified EPOCH regimen. One-year overall survival was 56% (95% CI 24–79%), without clear differences based on HIV status. PBL occurs in Malawi in HIV-positive and HIV- negative individuals and can be treated successfully with curative intent, even in a low-resource setting in SSA.


Overall survival of plasmablastic lymphoma patients in Lilongwe stratified by HIV status. No difference was found between HIV+ and HIV- patients by log-rank test